Huselton E, Rettig MP, Campbell K, Cashen AF, Dipersio JF, Gao F, Jacoby MA, Pusic I, Romee R, Schroeder MA, et al. Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS. Leuk Res. 2021;110:106713.